ECE2014 Poster Presentations Endocrine tumours and neoplasia (99 abstracts)
Combined therapy PRRT with long acting somatostatin analogue: results of 7 years’ experience
Anna Sowa-Staszczak 1 , Agnieszka Stefanska 1 , Monika Buziak-Bereza 1 , Malgorzata Trofimiuk-Muldner 1 , Renata Mikolajczak 2 , Monika Tomaszuk 1 & Alicja Hubalewska-Dydejczyk 1
1Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland; 2Radioisotope Center POLATOM, National Centre for Nuclear Research, Otwock, Poland.
Introduction: The aim of this study was to assess the survival rate of patients with disseminated or inoperable neuroendocrine tumors (NETs) after PRRT with the use of 90Y-DOTATATE combined with long acting somatostatin analogue.
Materials and methods: 72 patients were treated with PRRT in our Department. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administrated in three to five cycles, repeated every 1–9 weeks. After PRRT, patients have been further treated with cold long acting somatostatin analogues to the progression of the disease.
Results: Out of 72 90Y-DOTATATE treated patients, 22 died after completing the therapy, among them two due to myocardial infarction. After 12 month follow-up, stabilization of disease was observed in 63%, partial remission in 25%, and progression in 12% in this group of patients. The progression free survival (PFS) was found to be 41.27 months and the event-free survival (EFS) – 37.73 months. The median overall survival (OS) was not reached. According to the literature (Ćwikła et al. 2010) in group of 57 patients treated by 90Y-DOTATATE up to a cumulative activity of 15.2 GBq PFS and OS was about 17 and 22 months respectively. During follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. An increase of creatinine level and decrease of GFR values in the observation period were found, but these were clinically insignificant symptoms of transient nephrotoxicity.
Conclusion: PRRT and further treatment with long acting somatostatin analogues may extended the survival of disseminated patients with NETs. Long-term patients benefit in the form of symptomatic relief and tumour mass reduction after 90Y-DOTATATE therapy was also observed.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more